Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome

Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2002-05, Vol.61 (5), p.414-421
Hauptverfasser: Williams, F M K, Chinn, S, Hughes, G R V, Leach, R M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 421
container_issue 5
container_start_page 414
container_title Annals of the rheumatic diseases
container_volume 61
creator Williams, F M K
Chinn, S
Hughes, G R V
Leach, R M
description Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.
doi_str_mv 10.1136/ard.61.5.414
format Article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A86035266</galeid><sourcerecordid>A86035266</sourcerecordid><originalsourceid>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</originalsourceid><addsrcrecordid>eNp9kt-L1DAQx4Mo3t7pm89SFPHFrknzo-nLwbl4_uA45fDHY0jTdDdrm6xJe7j_vbNsuT1hkRCGyXzynclkEHpG8JwQKt7q2MwFmfM5I-wBmhEmZF5ggR-iGcaY5qwS5Qk6TWkNLpZEPkYnhFS8KgWfoZtFdIMzustc13mbUuZ8lrZpsL0zWTduxpTZuB1WttdDSOBp32Tggh3cZhUS7M5tXAO3fBNDb5-gR63ukn062TP0_fL9t8XH_OrLh0-Li6u85gVnudAFrZmUuqZlU2lmGDUSC4MbVtSyopJUzNq6agsmGeGSsRZL04oGjKgNpmfofK-7GeveNsb6IepObaLrddyqoJ36N-LdSi3DrSIlZ7jiIPByEojh92jToNZhjB5qBqQsIWPJK6Be7Kml7qxyvg0gZnqXjLqQAlNeCAHQmyPQ0noLiYO3rYPj-3h-BIfV7Np-jJ_kTQwpRdvevZJgtZsCBVOgBFFcwRQA_vx-Zw7w9O0AvJoAneDv26i9cenAUUFZQeShTgcD8ecuruMvJUpacnX9Y6Gub8jnd5c_v6od_3rP1_36_yX-Bfmt1iY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1777844759</pqid></control><display><type>article</type><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</creator><creatorcontrib>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</creatorcontrib><description>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.5.414</identifier><identifier>PMID: 11959765</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Acute Physiology and Chronic Health Evaluation (score) ; acute respiratory distress syndrome ; Adolescent ; Adult ; Age Factors ; Age of Onset ; Aged ; ANA ; Anticoagulants ; Antigens ; antinuclear antibodies ; Antiphospholipid syndrome ; Antiphospholipid Syndrome - drug therapy ; Antiphospholipid Syndrome - mortality ; APACHE ; APS ; ARDS ; Biological and medical sciences ; C reactive protein ; Child ; confidence interval ; Critical Care ; Critical Illness ; CRP ; Cyclophosphamide - therapeutic use ; Development and progression ; ENA ; erythrocyte sedimentation rate ; ESR ; Extended Report ; extractable nuclear antigens ; Female ; Hematology ; Humans ; ICU ; Illnesses ; Immunoglobulins ; Immunosuppressive Agents - therapeutic use ; Infections ; intensive care ; intensive care unit ; Intensive care units ; Kidney diseases ; Kidney Diseases - drug therapy ; Kidney Diseases - mortality ; Laboratories ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - mortality ; Male ; Medical prognosis ; Medical sciences ; Middle Aged ; Mortality ; Physiology ; Prednisolone - therapeutic use ; Proportional Hazards Models ; Regression Analysis ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; SLE ; Survival Rate ; Systemic lupus erythematosus ; Thrombosis ; WCC ; white cell count</subject><ispartof>Annals of the rheumatic diseases, 2002-05, Vol.61 (5), p.414-421</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2002 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2002 Copyright 2002 by Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</citedby><cites>FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754095/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1754095/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13634218$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11959765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Williams, F M K</creatorcontrib><creatorcontrib>Chinn, S</creatorcontrib><creatorcontrib>Hughes, G R V</creatorcontrib><creatorcontrib>Leach, R M</creatorcontrib><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</description><subject>Acute Physiology and Chronic Health Evaluation (score)</subject><subject>acute respiratory distress syndrome</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>ANA</subject><subject>Anticoagulants</subject><subject>Antigens</subject><subject>antinuclear antibodies</subject><subject>Antiphospholipid syndrome</subject><subject>Antiphospholipid Syndrome - drug therapy</subject><subject>Antiphospholipid Syndrome - mortality</subject><subject>APACHE</subject><subject>APS</subject><subject>ARDS</subject><subject>Biological and medical sciences</subject><subject>C reactive protein</subject><subject>Child</subject><subject>confidence interval</subject><subject>Critical Care</subject><subject>Critical Illness</subject><subject>CRP</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Development and progression</subject><subject>ENA</subject><subject>erythrocyte sedimentation rate</subject><subject>ESR</subject><subject>Extended Report</subject><subject>extractable nuclear antigens</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>ICU</subject><subject>Illnesses</subject><subject>Immunoglobulins</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infections</subject><subject>intensive care</subject><subject>intensive care unit</subject><subject>Intensive care units</subject><subject>Kidney diseases</subject><subject>Kidney Diseases - drug therapy</subject><subject>Kidney Diseases - mortality</subject><subject>Laboratories</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Physiology</subject><subject>Prednisolone - therapeutic use</subject><subject>Proportional Hazards Models</subject><subject>Regression Analysis</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>SLE</subject><subject>Survival Rate</subject><subject>Systemic lupus erythematosus</subject><subject>Thrombosis</subject><subject>WCC</subject><subject>white cell count</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kt-L1DAQx4Mo3t7pm89SFPHFrknzo-nLwbl4_uA45fDHY0jTdDdrm6xJe7j_vbNsuT1hkRCGyXzynclkEHpG8JwQKt7q2MwFmfM5I-wBmhEmZF5ggR-iGcaY5qwS5Qk6TWkNLpZEPkYnhFS8KgWfoZtFdIMzustc13mbUuZ8lrZpsL0zWTduxpTZuB1WttdDSOBp32Tggh3cZhUS7M5tXAO3fBNDb5-gR63ukn062TP0_fL9t8XH_OrLh0-Li6u85gVnudAFrZmUuqZlU2lmGDUSC4MbVtSyopJUzNq6agsmGeGSsRZL04oGjKgNpmfofK-7GeveNsb6IepObaLrddyqoJ36N-LdSi3DrSIlZ7jiIPByEojh92jToNZhjB5qBqQsIWPJK6Be7Kml7qxyvg0gZnqXjLqQAlNeCAHQmyPQ0noLiYO3rYPj-3h-BIfV7Np-jJ_kTQwpRdvevZJgtZsCBVOgBFFcwRQA_vx-Zw7w9O0AvJoAneDv26i9cenAUUFZQeShTgcD8ecuruMvJUpacnX9Y6Gub8jnd5c_v6od_3rP1_36_yX-Bfmt1iY</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>Williams, F M K</creator><creator>Chinn, S</creator><creator>Hughes, G R V</creator><creator>Leach, R M</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>BMJ Publishing Group Ltd</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20020501</creationdate><title>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</title><author>Williams, F M K ; Chinn, S ; Hughes, G R V ; Leach, R M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b5254-6a23b488ab37d9a4c43c806c0d42b8938194eeb9f248415844f08cf6df086bc03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Acute Physiology and Chronic Health Evaluation (score)</topic><topic>acute respiratory distress syndrome</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>ANA</topic><topic>Anticoagulants</topic><topic>Antigens</topic><topic>antinuclear antibodies</topic><topic>Antiphospholipid syndrome</topic><topic>Antiphospholipid Syndrome - drug therapy</topic><topic>Antiphospholipid Syndrome - mortality</topic><topic>APACHE</topic><topic>APS</topic><topic>ARDS</topic><topic>Biological and medical sciences</topic><topic>C reactive protein</topic><topic>Child</topic><topic>confidence interval</topic><topic>Critical Care</topic><topic>Critical Illness</topic><topic>CRP</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Development and progression</topic><topic>ENA</topic><topic>erythrocyte sedimentation rate</topic><topic>ESR</topic><topic>Extended Report</topic><topic>extractable nuclear antigens</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>ICU</topic><topic>Illnesses</topic><topic>Immunoglobulins</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infections</topic><topic>intensive care</topic><topic>intensive care unit</topic><topic>Intensive care units</topic><topic>Kidney diseases</topic><topic>Kidney Diseases - drug therapy</topic><topic>Kidney Diseases - mortality</topic><topic>Laboratories</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Physiology</topic><topic>Prednisolone - therapeutic use</topic><topic>Proportional Hazards Models</topic><topic>Regression Analysis</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>SLE</topic><topic>Survival Rate</topic><topic>Systemic lupus erythematosus</topic><topic>Thrombosis</topic><topic>WCC</topic><topic>white cell count</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williams, F M K</creatorcontrib><creatorcontrib>Chinn, S</creatorcontrib><creatorcontrib>Hughes, G R V</creatorcontrib><creatorcontrib>Leach, R M</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williams, F M K</au><au>Chinn, S</au><au>Hughes, G R V</au><au>Leach, R M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>61</volume><issue>5</issue><spage>414</spage><epage>421</epage><pages>414-421</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives: To investigate the causes, course, and outcome of critical illness requiring emergency admission to the intensive care unit (ICU) in patients with systemic lupus erythematosus (SLE) or the antiphospholipid syndrome (APS), or both. Methods: Critically ill patients with SLE or APS, or both, admitted to a London teaching hospital ICU over a 15 year period were studied. Demographic, diagnostic, physiological, laboratory, and survival data were analysed. Kaplan-Meier survival curves were constructed by age, time from first diagnosis of SLE, and time from first ICU admission. The log rank test and a backwards stepwise Cox regression were used to identify factors associated with reduced survival. Results: Sixty one patients with SLE alone (39%) and/or APS (61%) required 76 emergency admissions to the ICU. Patients had high severity of illness scores (median APACHE II 22 (range 8–45)) and multiorgan dysfunction. The primary diagnoses for patients admitted were infection in 31/76 (41%), renal disease in 16/76 (21%), cardiovascular disease in 12/76 (16%), and coagulopathies in 11/76 (14%). The commonest secondary diagnosis was renal dysfunction (49%). Factors associated with an increased risk of death were cyclophosphamide before admission, low white cell count, and high severity of illness score. Before adjustment for these factors renal disease had a strong adverse effect on long term survival (analysis by age at diagnosis p=0.005, analysis by time since first ICU admission, p=0.07). After adjustment, infection at admission to ICU was associated with an increased ICU mortality (p=0.02) and was the cause of death in 13/17 patients who died in the ICU. Similarly, after adjustment, APS was associated with reduced ICU survival (p=0.1) and reduced long term (p=0.03) survival. Seventeen patients (28%) died in the ICU, and 31 patients (51%) had died by the last follow up. Median time from ICU admission to death was four years. Overall five year survival from the first ICU admission was 43%. Conclusion: Critical illness requiring ICU admission may occur in patients with SLE and APS. In this study, ICU survival was better than previously described, but long term survival was poor. Cyclophosphamide administration, low white cell count, and high severity of illness score were associated with reduced survival. Before adjustment for these factors, only renal disease had an adverse effect on outcome but after adjustment, infection and APS reduced survival.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>11959765</pmid><doi>10.1136/ard.61.5.414</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2002-05, Vol.61 (5), p.414-421
issn 0003-4967
1468-2060
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1754095
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Acute Physiology and Chronic Health Evaluation (score)
acute respiratory distress syndrome
Adolescent
Adult
Age Factors
Age of Onset
Aged
ANA
Anticoagulants
Antigens
antinuclear antibodies
Antiphospholipid syndrome
Antiphospholipid Syndrome - drug therapy
Antiphospholipid Syndrome - mortality
APACHE
APS
ARDS
Biological and medical sciences
C reactive protein
Child
confidence interval
Critical Care
Critical Illness
CRP
Cyclophosphamide - therapeutic use
Development and progression
ENA
erythrocyte sedimentation rate
ESR
Extended Report
extractable nuclear antigens
Female
Hematology
Humans
ICU
Illnesses
Immunoglobulins
Immunosuppressive Agents - therapeutic use
Infections
intensive care
intensive care unit
Intensive care units
Kidney diseases
Kidney Diseases - drug therapy
Kidney Diseases - mortality
Laboratories
Lupus
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - mortality
Male
Medical prognosis
Medical sciences
Middle Aged
Mortality
Physiology
Prednisolone - therapeutic use
Proportional Hazards Models
Regression Analysis
Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis
SLE
Survival Rate
Systemic lupus erythematosus
Thrombosis
WCC
white cell count
title Critical illness in systemic lupus erythematosus and the antiphospholipid syndrome
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T18%3A37%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Critical%20illness%20in%20systemic%20lupus%20erythematosus%20and%20the%20antiphospholipid%20syndrome&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Williams,%20F%20M%20K&rft.date=2002-05-01&rft.volume=61&rft.issue=5&rft.spage=414&rft.epage=421&rft.pages=414-421&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.5.414&rft_dat=%3Cgale_pubme%3EA86035266%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1777844759&rft_id=info:pmid/11959765&rft_galeid=A86035266&rfr_iscdi=true